GINA no longer recommends treating adults/adolescents with asthma with short-acting
bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a …

Asthma is highly prevalent and sometimes deadly, especially in certain groups. The 2019
Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated …

The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …

Background This asthma guideline update focuses on the management of individuals with
asthma at the mild end of the spectrum. It applies to children 1 year of age and over and …

Abstract The Global Initiative for Asthma (GINA) was established in 1993 by the World
Health Organization and the US National Heart Lung and Blood Institute to improve asthma …

Asthma is a heterogeneous lung disease, usually characterised by chronic airway
inflammation. Although evidence-based treatments are available in most countries, asthma …

Background Asthma is a common respiratory disease among both adults and children and
short acting inhaled beta‐2 agonists are used widely for'reliever'bronchodilator therapy …

Background Long-acting ß 2-agonists (LABA) in combination with inhaled corticosteroids
(ICS) are increasingly prescribed in asthmatic children. Objectives To compare the safety …

BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and
recent evidence suggested a detrimental effect on asthma control as well as an increased …

abstract Asthma is characterized by chronic airway inflammation, variable airway narrowing,
and sensory nerve irritation, which manifest as wheezing, dyspnea, chest tightness, and …